Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S. FDA) for Axitinib Tablets, 1 mg and 5 mg, the generic version of Inlyta®1 Tablets, 1 mg and 5 mg, of PF Prism C.V.
According to IQVIA™ sales data for the 12 month period ending October 2020, the Inlyta® Tablets, 1 mg and 5 mg market2 achieved annual sales of approximately $518.8 million*.
Glenmark's current portfolio consists of 166 products authorized for distribution in the U.S. marketplace and 45 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.471.45 as compared to the previous close of Rs. 468.75. The total number of shares traded during the day was 83915 in over 1790 trades.
The stock hit an intraday high of Rs. 478.5 and intraday low of 470.05. The net turnover during the day was Rs. 39727162.
1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIA™ National Sales Perspectives: Retail & Non-Retail, October 2020